Fund Holdings — Patient Square Capital LP

Total Portfolio Value
$373.86M
Total Bought
$54.26M
Total Sold
$37.49M
Net Transaction
+$16.76M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
ROIVANT SCIENCES LTD(ROIV)12,480,00012,480,0000140,650188,82250.51%+48,173
ABIVAX SA(ABVX)0151,833+151,833012,8913.45%+12,891
INSMED INC(INSM)358,800326,400-32,40036,11047,00512.57%+10,895
CIDARA THERAPEUTICS INC15,000121,000+106,00073111,5873.10%+10,856
CELCUITY INC(CELC)0100,000+100,00004,9401.32%+4,940
DIANTHUS THERAPEUTICS INC(DNTH)0125,000+125,00004,9191.32%+4,919
UNIQURE NV(QURE)075,000+75,00004,3781.17%+4,378
PHARVARIS N V
COM
244,283345,381+101,0984,2998,6172.30%+4,318
AMYLYX PHARMACEUTICALS INC(AMLX)0316,312+316,31204,2991.15%+4,299
ASSEMBLY BIOSCIENCES INC0135,182+135,18203,4610.93%+3,461
MIRUM PHARMACEUTICALS INC(MIRM)113,462104,262-9,2005,7747,6432.04%+1,869
EYEPOINT PHARMACEUTICALS INC(EYPT)1,352,8371,011,839-340,99812,73014,4093.85%+1,678
AVALO THERAPEUTICS INC(AVTX)0100,000+100,00001,2710.34%+1,271
PERSPECTIVE THERAPEUTICS INC(CATX)0349,323+349,32301,1980.32%+1,198
DISC MEDICINE INC(IRON)74,00074,00003,9194,8901.31%+971
OCULAR THERAPEUTIX INC(OCUL)817,699715,000-102,6997,5888,3582.24%+770
AGIOS PHARMACEUTICALS INC(AGIO)139,732133,827-5,9054,6475,3721.44%+724
ALLOGENE THERAPEUTICS INC2,635,0002,981,396+346,3962,9783,6970.99%+719
ENLIVEN THERAPEUTICS INC245,838250,838+5,0004,9325,1351.37%+203
GERON CORP(GERN)716,000845,000+129,0001,0101,1580.31%+148
VYNE THERAPEUTICS INC.(YARW)317,0330-317,0335230—-523
NURIX THERAPEUTICS INC(NRIX)412,296437,237+24,9414,6964,0401.08%-656
KYMERA THERAPEUTICS INC(KYMR)140,00092,592-47,4086,1105,2411.40%-869
LIQUIDIA CORPORATION(LQDA)1,020,000400,000-620,00012,7099,0962.43%-3,613
ARGENX SE(ARGX)29,00015,500-13,50015,98511,4323.06%-4,553
SCHOLAR ROCK HOLDING CORPORATION(SRRK)154,0000-154,0005,4550—-5,455
CULLINAN THERAPEUTICS, INC.(CGEM)868,8970-868,8976,5430—-6,543
Page 1 of 1
Patient Square Capital LP — 13F Holdings — Q3 2025 | TickerTrail